Glaukos Corp. in Laguna Hills said Chief Financial Officer Richard Harrison will retire next year.
Glaukos makes the iStent implant used to treat glaucoma, an eye disease that is a major cause of blindness.
The device maker said in a statement that Harrison, who joined Glaukos in 2008, would remain CFO until a successor’s named “and he has agreed to assist with an orderly transaction.”
Harrison was executive vice president and chief financial officer at Biolase Technology Inc., now Irvine-based Biolase Inc., prior to joining Glaukos.
Glaukos is searching for Harrison’s successor.
Shares of Glaukos were up 1% in recent trading to a market value of $1.1 billion.
